n INTRODUCTION S ystemic sclerosis (SSc) is a connective tissue disease characterized by a microvessel dysfunction, the aberrant activation of the immune system, and the deposition of extracellular matrix in skin and viscera. Endothelial cells and contractile myofibroblasts, involved in microvessel dysfunction, contribute to the first step in the pathogenesis of the disease, whereas the immune system may play a secondary role. Klotho is a trans-membrane, soluble and secreted protein that displays enzymatic and co-receptor functions, being involved in the prevention of aging, in the calcium-phosphate balance and in the reparative and fibrotic processes (1, 2) . Transgenic klotho-/-mice develop a phenotype characterized by accelerated aging, atherosclerosis, hyper-phosphatemia, osteoporosis, cutaneous atrophy and emphysema and have a lower likelihood in cutaneous wound healing (3) . As klotho seems to play an essential role in the maintenance of vessel tone control, in tissue regeneration and reparation and in the electrolytic balance, a deficit in the concentration of this molecule could explain some phenotypic aspects of SSc, like microvessel dysfunction, calcinosis and fibrosis. The primary objective of this study was to evaluate klotho as a biomarker of SSc, to measure its concentration as a soluble molecule in the peripheral blood of SSc patients and to compare it with healthy controls. The secondary objective was to find any significant association with clinical, laboratory and instrumental manifestations of the disease. Our cohort consisted of 69 SSc patients (61 females, mean age 64.5±12.5 years, median disease duration 9.0 u s e Our cohort consisted of 69 SSc patients (61 females, mean age 64.5±12.5 years, median disease duration 9.0 (IQR 8) years) and 77 healthy controls (28 females, mean age 49.7±10.2 years). In the group of SSc patients, u s e (IQR 8) years) and 77 healthy controls (28 females, mean age 49.7±10.2 years). In the group of SSc patients, 19 (27.5%) suffered from a diffuse form of SSc. All patients were receiving IV prostanoids, and some of u s e 19 (27.5%) suffered from a diffuse form of SSc. All patients were receiving IV prostanoids, and some of them were concomitantly treated with immunosuppressive drugs (prednisone, hydroxychloroquine, mofetil u s e them were concomitantly treated with immunosuppressive drugs (prednisone, hydroxychloroquine, mofetil mycophenolate, methotrexate, cyclosporin A and azathioprine). The median serum concentration of klotho was u s e mycophenolate, methotrexate, cyclosporin A and azathioprine). The median serum concentration of klotho was o n l y Blood samples obtained from both SSc patients and healthy controls were analysed by an ELISA assay for o n l y Blood samples obtained from both SSc patients and healthy controls were analysed by an ELISA assay for the detection of human klotho. SSc patients were globally evaluated for disease activity and assessed through o n l y the detection of human klotho. SSc patients were globally evaluated for disease activity and assessed through the modified Rodnan's Skin Score, Medsger's scale, pulmonary function tests, 2D-echocardiography, nailfold o n l y the modified Rodnan's Skin Score, Medsger's scale, pulmonary function tests, 2D-echocardiography, nailfold
Our cohort consisted of 69 SSc patients (61 females, mean age 64.5±12.5 years, median disease duration 9.0 o n l y Our cohort consisted of 69 SSc patients (61 females, mean age 64.5±12.5 years, median disease duration 9.0 (IQR 8) years) and 77 healthy controls (28 females, mean age 49.7±10.2 years). In the group of SSc patients, o n l y (IQR 8) years) and 77 healthy controls (28 females, mean age 49.7±10.2 years). In the group of SSc patients, klotho in systemic sclerosis ORIGINAL PAPER n MATERIALS AND METHODS Sixty-nine consecutive SSc patients, according to the 2013 EULAR/ACR criteria (4), and 77 healthy controls were enrolled in our study. After signing an informed consent, venous blood samples obtained from both patients and controls were collected and centrifuged. Sera were analysed through an ELISA assay, aiming to detect the human soluble klotho by means of a monoclonal anti-KL antibody and a KL-HRP conjugate (My Biosource, CA, USA), with a sensitivity of 0.1 ng/mL. SSc patients were assessed for the most specific clinical manifestations (including Raynaud's phenomenon, digital ulcers, calcinosis), through the Medsger's scale score (5) for the severity of global visceral involvement and through the modified Rodnan's Skin Score (mRSS) for cutaneous involvement. Moreover, the demographic and clinical data concerning pulmonary function tests (forced vital capacity or FVC; diffusing capacity/transfer factor of the lung for carbon monoxide per unit alveolar volume or DLCO/AV; chest high resolution computer tomography or HRCT scan), cardiac indexes (2D echocardiography or 2D-ECHO) as indirect estimator of the risk of pulmonary artery hypertension (PAH), nailfold capillaroscopic pattern and laboratory tests (serum creatinine level; erythrocyte sedimentation rate or ESR; C-reactive protein or CRP; autoantibodies), as well as concomitant pharmacologic treatments were also recorded for every single patient. Since klotho may be involved in the prevention of diabetes, renal failure and bronchial obstructive disease, these disorders were considered as exclusion criteria. 
Statistical analysis

ORIGINAL PAPER
U test for unpaired samples, a significant reduction in serum klotho concentration in patients compared to controls was detected (p<0.001), Figure 1 . However, the cohorts of patients and controls significantly differed for gender (p<0.001) and age (p<0.001). Global median concentration of serum klotho was 0.27 ng/mL (IQ 0.61; range 0.00-1.85) in females and 0.63 ng/mL (IQ 0.68, range 0.00-1.70) in males, with a significant difference between males and females (p<0.001). Among controls, median serum klotho concentrations were lower in females (median values 0.45 ng/mL; IQ 0.46, range 0.00-1.10) than males (median values 0.71 ng/mL, IQ 0.51, range 0.00-1.70), although this difference was not statistically significant (2-tailed T-test for unpaired samples; p=0.27); on the contrary, in the patients' group median klotho serum concentrations were higher in females (median values 0.24 ng/mL; IQ 0.66, range 0.04-1.85) than males (median values 0.19 ng/ mL, IQ 0.15, range 0.13-0.37) and this difference was statistically significant (twotailed Mann Whitney U test for unpaired samples; p=0.02). Age minimally affected the concentration of klotho in the overall population (p=0.05; F 3.89; p=0.26), although not reaching significance when the group of SSc patients and controls were analysed separately (p=0.47; F 0.52; p=0.008 for SSc patients and p=0.48; F 0.49; p=0.007 for controls). In the group of SSc patients, Spearman correlation showed no significant association between klotho serum levels and disease activity, concerning either clinical, laboratory and instrumental findings.
n DISCUSSION Klotho is a 130 kDa protein synthetized in many tissues as a soluble, secreted or single-pass trans-membrane form, initially considered as an anti-aging factor. Three genes are responsible for the codification of the a, b and g isoforms of klotho. a-klotho is mainly produced in the arterial tree, skin, kidney and gut epithelia, neuronal cells and endocrine tissues (7). b-klotho, sharing a 41% amino acid homology with a-klotho, is expressed in adipose tissue, liver and pancreas (8) . The entire molecule of klotho contains a single-pass trans-membrane domain and two extracellular domains, known as KL1 and KL2 domains and, following a mechanism of alternative splicing, a secreted isoform of klotho, containing only the KL1 domain, may be generated and released in the extracellular environment. Furthermore, once expressed on the cellular surface, the extracellular KL1 and KL2 domains may be cleaved by secretases and released as soluble klotho (9) . Trans-membrane klotho may interact with receptors on neighbouring cells, acting in a paracrine axis, whereas soluble klotho may circulate in the bloodstream and exert its effects on distant organs as an endocrine factor. The KL1 and KL2 domains of both transmembrane and soluble klotho display b-glucuronidase and sialidase activity by removing glucidic residuals from transient receptor potential vanilloid receptor-related (TRPV5) and TRP canonical-1 (TRPC-1), thus regulating calcium (Ca) 2+ ions influx into epithelial and endothelial (11) . Furthermore, the authors demonstrated in the same experiment that the addition of soluble klotho without FGF23 to mouse aorta rings induced vasoconstriction and the production of ROS. The increase in endothelial NO following soluble klotho administration could explain the antagonistic effects of klotho to monocrotalineinduced experimental PAH in murine models (12) . However, the evaluation of soluble a-klotho in the peripheral blood from 64 precapillary PAH patients did not find a significant association with haemodynamic findings (13) . It suggests that soluble klotho exerts its hormonal effects modulating the vessel tone according to the presence or not of FGF23 and that a-and b-klotho may have different roles in controlling myo-contractile cells and in preserving endothelial integrity. Moreover, it has been demonstrated that b-klotho, but not a-klotho, complexes with FGF19 and FGFR4 expressed in the biliary tract, controlling bile acid synthesis (14) . b-klotho may account for the glucidic and lipidic balance, reducing insulin resistance and visceral adiposity, and contributing therefore to minimize vascular damage through different biologic mechanisms. A deficit of klotho has been associated with oxidative stress and mitochondrial damage, which represent specific hallmarks of the endothelial dysfunction in SSc, and to the modulation in the expression of p53 and p21 that accelerates the cell-cycle arrest in G1 phase and cell senescence, generating oxidative stress and autophagy (9) . Moreover, soluble klotho binds to several Wnt proteins inhibiting their biological activity, including keratinocyte ageing and connective tissue fibrosis. Klotho-/-mice have a short lifespan and an elderly phenotype characterized by a deficit in osteoclasts and osteoblasts, diffuse bone demineralization and vascular tree calcifications. It has been reported that a deficit in human klotho may account for severe tumoral calcinosis (15) . Subcutaneous calcinosis is a common finding in SSc and a deficit in serum klotho concentration could be responsible for Ca 2+ lumps. Moreover, a deficit in klotho could induce a delay in cutaneous ulcer healing related to a reduced apposition of collagen 1 and 3 in wound tissue (3). However, although SSc patients often suffer from prolonged cutaneous ulcer healing times, the reduced production of collagen observed in klothodeficient mice contrasts with the aberrant deposition of extracellular matrix in SSc. A recent experiment on human primary dermal microvascular endothelial cells and dermal fibroblasts showed that klotho may control the expression of genes involved in tissue repair and angiogenesis, counteracting the aberrant production of extracellular matrix and favouring neovessel sprouting (16) . The possible pathway presided by a-and b-klotho is illustrated in Figure 2 . Our data demonstrate that the median serum concentration of klotho was sig- 
nificantly lower in SSc patients than in healthy controls. These results are in accordance with the hypothesis that a deficit of klotho may account for many manifestations of the disease, including ulcer healing delay, lung fibrosis, calcinosis, renal crisis. Although a standardised range for serum klotho is unavailable, our results are in line with serum klotho levels shown in previous studies on human healthy subjects (17, 18) . However, due the consecutive enrolment and the design of the study, the cohort of patients significantly differed from controls with respect to gender and age. Klotho concentrations were lower in patients than in controls both in males and females, with the lower concentrations in male patients. Gender may have represented a bias for our analysis; nevertheless, SSc may play an additional role in influencing klotho serum levels, altering the male/female ratio in the group of patients. However, two previous studies measuring serum klotho concentration through an ELISA kit in healthy subjects did not suggest a significant influence of gender on klotho serum concentration (17, 19) . Furthermore, other studies on non-scleroderma-patient populations reported higher serum klotho concentrations in female than in male patients (20, 21) . These data are in line with our results, and may suggest that chronic diseases, including SSc, induce an imbalance of the serum klotho concentration with a more pronounced effect on male patients. On the contrary, age did not affect the overall concentration of serum klotho in both cohorts. Unfortunately, to our knowledge, no evaluation of soluble klotho in the sera of patients affected by connective tissue diseases has been reported until today. A reduced concentration of a-klotho in the cerebrospinal fluid has been associated to neuropsychiatric systemic lupus erythematosus (NSLE) in a multivariate analysis on 84 neuropsychiatric patients (22) . Similarly, an impairment in genetic expression and a deficient b-glucuronidase activity of klotho has been demonstrated in CD4+ T lymphocytes from rheumatoid arthritis (RA) patients, and associated with premature senescence of this pool of cells (23) . In a murine model of autoimmune colitis, it has been demonstrated that cytokines tumour necrosis factor (TNF) and interferon-g reduced the transcription of the klotho gene in renal epithelial cells (24) . SSc seems to display many phenotypic aspects compatible with a deficit of klotho. However, we did not find any significant association between the serum concentration of klotho and the likelihood of undergoing a specific manifestation of the disease. The most important limits of this study consist in the number of subjects involved, in the enrolment of patients coming from mismatched cohorts for gender and age, in the measurement of whole soluble klotho (without any distinction between a-klotho and b-klotho), in the lack of evaluation of secreted, soluble and trans-membrane isoforms, and perhaps in the low sensitiv- o n l y ity of the ELISA test. Polymorphic variants of the klotho gene were not assessed, since they could explain a quantitative or a qualitative deficit of the molecule. Finally, given the central role of klotho in calcium/ phosphate balance and in bone remodelling, the regular intake of calcium and cholecalciferol in 20 osteoporotic patients and the lack of a control group could have added further bias to our analysis, although no significant association was recorded between serum klotho concentration and the odds of having osteoporosis in the SSc cohort. Moreover, a recent work by Chalhoub et al. failed to assign sufficient relevance to soluble klotho as a biomarker of bone resorption and fracture risk (25) . 
